ESMO Breast Cancer Spotlight | Conferences

An Overview of the MERIBEL Study in HER2-Negative Breast Cancer

October 13, 2016

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the MERIBEL study during an interview at the 2016 ESMO Congress.

Ribociclib/Letrozole Combination an Important Advance in HR+ Metastatic Breast Cancer

October 10, 2016

Findings of a recent multicenter randomized trial showed postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer (MBC) had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to endocrine therapy.